FIREBRICK PHARMA LIMITED — Share Issue/Capital Change 2026

Jun 2, 2026

FirebrickPharma

2 June 2026

ASX Release

Notice under Section 708A of the Corporations Act

This notice is given by Firebrick Pharma Limited (Issuer or Company) (ASX:FRE) under section 708A(5)(e) of the Corporations Act 2001 (Cth) ("Act").

The Company has issued 220,000 ordinary fully paid shares to a consultant in lieu of service fees at an issue price of $0.05 per ordinary fully paid share ("Issued Shares").

In accordance with section 708A(5)(e) of the Act, the Company gives notice that:

1. the Issued Shares were issued without disclosure to investors under Part 6D.2 of the Act;
2. as at the date of this notice, the Company has complied with the provisions of Chapter 2M of the Act, as they apply to the Company and sections 674 and 674A of the Act; and
3. as at the date of this notice there is no information that is 'excluded' information within the meanings of section 708A(7) and 708A(8) of the Act, being information:

a) that has been excluded from a continuous disclosure notice in accordance with the ASX Listing Rules;
b) that investors and their professional advisers would reasonably require for the purposes of making and informed assessment of:

i. the assets and liabilities, financial position and performance, profits and losses and prospects of the Company; or
ii. the rights and liabilities attaching to the Securities.

This announcement has been authorised for release by the Board of Firebrick Pharma Limited.

Yours faithfully

Stephen Buckley

Company Secretary

Firebrick Pharma Ltd | ABN 64 157 765 896 | L10, 440 Collins St. Melbourne, VIC, 3000, Australia

P: 1300 301 874 | W: firebrickpharma.com

in

f

---

FirebrickPharma

About Firebrick (ASX:FRE)

Firebrick Pharma is developing and commercialising novel formulations and uses of povidone-iodine (PVP-I). Its first product, Nasodine® Nasal Spray (0.5% PVP-I), has been introduced into the United States, Singapore, and Fiji & South Pacific. Nasodine Nasal Spray was also recently approved for marketing in Indonesia and the Company is pursuing approval in the Philippines and other markets. Nasodine® Throat Spray is the first follow-on product, and is now available in Singapore and Fiji. Firebrick recently announced plans for a total of up to four products in the Nasodine range and expansion of sales to up to 10 markets over three years. For further information, visit firebrickpharma.com

Contacts:

Media contact:
Matthew Wright, NWR Communications
matt@nwrcommunications.com.au

Shareholder Company contact:
Kam Watson, Firebrick Pharma
investors@firebrickpharma.com

Firebrick Pharma Ltd | ABN 64 157 765 896 | L10, 440 Collins St. Melbourne, VIC, 3000, Australia
P: 1300 301 874 | W: firebrickpharma.com
in